Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects.

MLA

Kamli, Hossam, et al. “Overcoming Sunitinib Resistance with Tocilizumab in Renal Cell Carcinoma: Discordance between in Vitro and in Vivo Effects.” Biochemical & Biophysical Research Communications, vol. 586, Jan. 2022, pp. 42–48. EBSCOhost, https://doi.org/10.1016/j.bbrc.2021.11.069.

APA

Kamli, H., Owens, E. P., Vesey, D. A., Prasanna, R., Li, L., Gobe, G. C., & Morais, C. (2022). Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects. Biochemical & Biophysical Research Communications, 586, 42–48. https://doi.org/10.1016/j.bbrc.2021.11.069

Chicago

Kamli, Hossam, Evan P. Owens, David A. Vesey, Rajagopalan Prasanna, Li Li, Glenda C. Gobe, and Christudas Morais. 2022. “Overcoming Sunitinib Resistance with Tocilizumab in Renal Cell Carcinoma: Discordance between in Vitro and in Vivo Effects.” Biochemical & Biophysical Research Communications 586 (January): 42–48. doi:10.1016/j.bbrc.2021.11.069.